Biosimilars for psoriasis: clinical studies to determine similarity.

about

P2860

Q46023398-61A5C579-98DD-4EB0-8243-8FBE3358D6A8 Q47859049-7A972BC3-5C77-4863-8130-70ACD2A8BE66 Q55008089-9F289936-C308-44C3-8B1B-AE9DABBC3366

P2860

Biosimilars for psoriasis: clinical studies to determine similarity.

Item

http://www.wikidata.org/entity/Q38957406

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Biosimilars for psoriasis: clinical studies to determine similarity.

@en

type

Item

label

Biosimilars for psoriasis: clinical studies to determine similarity.

@en

prefLabel

Biosimilars for psoriasis: clinical studies to determine similarity.

@en

P1476

Biosimilars for psoriasis: clinical studies to determine similarity

@en

P2093

A Blauvelt

http://www.w3.org/2001/XMLSchema#string

A Cohen

http://www.w3.org/2001/XMLSchema#string

E Prens

http://www.w3.org/2001/XMLSchema#string

H Young

http://www.w3.org/2001/XMLSchema#string

J van der Walt

http://www.w3.org/2001/XMLSchema#string

L Puig

http://www.w3.org/2001/XMLSchema#string

M Rajagopalan

http://www.w3.org/2001/XMLSchema#string

R Romiti

http://www.w3.org/2001/XMLSchema#string

S Chimenti

http://www.w3.org/2001/XMLSchema#string

P2860

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?

Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study.

Statistical and regulatory considerations in assessments of interchangeability of biological drug products.

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis.

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.

A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.

Analytical aspects of biosimilarity issues of protein drugs.

P304

23-33

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.15067

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27639072

http://www.w3.org/2001/XMLSchema#string

Biosimilars for psoriasis: clinical studies to determine similarity.

about

P2860

P2860

Biosimilars for psoriasis: clinical studies to determine similarity.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698